• All
  • Article Title
  • Abstract
  • Keywords
  • Author
  • Institution
  • Exploration of Targeted Anti-tumor Therapy

    eISSN: 2692-3114
    EiC: Nicola Normanno, Italy
    Frequency: Continuous Publication
    APC: $2,000 per article (See APC Waivers and Discounts)
    Publishing Model: Open Access
    Peer Review Model: Single Blind
    Indexing & Archiving: PubMed/PMC, Scopus, Google Scholar, DOAJ, CAS, Dimensions, Portico, etc. The journal is also the member of COPE.
    Follow the journal:
    Follow the journal:
    Articles
    Open Access
    Review
    Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation
    Neoantigen-based immunotherapy has emerged as a transformative approach in cancer treatment, offering precision medicine strategies that target tumor-specific antigens derived from genetic, transcri [...] Read more.
    Moawiah M Naffaa ... Valiko Begiashvili
    Published: April 27, 2025 Explor Target Antitumor Ther. 2025;6:1002313
    DOI: https://doi.org/10.37349/etat.2025.1002313
    View:171
    Download:7
    Times Cited: 0
    Open Access
    Review
    Cytokine-based immunotherapy for gastric cancer: targeting inflammation for tumor control
    Emerging cancer immunotherapy methods, notably cytokine-based ones that modify immune systems’ inflammatory reactions to tumor cells, may help slow gastric cancer progression. Cytokines, tiny sign [...] Read more.
    Mathan Muthu Chinakannu Marimuthu ... Hitesh Chopra
    Published: April 26, 2025 Explor Target Antitumor Ther. 2025;6:1002312
    DOI: https://doi.org/10.37349/etat.2025.1002312
    View:110
    Download:5
    Times Cited: 0
    Open Access
    Review
    Viral infections and immune modulation in bladder cancer: implications for immunotherapy
    This review explores the intricate relationship between viral infections and Bacillus Calmette-Guerin (BCG) efficacy, emphasizing immune modulation mechanisms that may influence treatment outcomes.  [...] Read more.
    Lívia Bitencourt Pascoal ... Leonardo O. Reis
    Published: April 24, 2025 Explor Target Antitumor Ther. 2025;6:1002311
    DOI: https://doi.org/10.37349/etat.2025.1002311
    This article belongs to the special issue Comprehensive Immunotherapy of Solid Tumors
    View:191
    Download:7
    Times Cited: 0
    Open Access
    Review
    Modulation of anti-tumour immunity by XPO1 inhibitors
    Exportin-1 (XPO1) is a nuclear export protein that, when overexpressed, can facilitate cancer cell proliferation and survival and is frequently overexpressed or mutated in cancer patients. As such,  [...] Read more.
    Jack G. Fisher ... Matthew D. Blunt
    Published: April 23, 2025 Explor Target Antitumor Ther. 2025;6:1002310
    DOI: https://doi.org/10.37349/etat.2025.1002310
    This article belongs to the special issue Immune Checkpoint Therapy and Biomarkers in Cancer
    View:285
    Download:10
    Times Cited: 0
    Open Access
    Case Report
    Eosinophil cytolysis with or without ETosis in four cases of human gastric cancer: a comparative ultrastructural study
    The ultrastructural morphology of eosinophil cytolysis and extracellular trap cell death (ETosis) has predominantly been examined in non-neoplastic eosinophil-associated diseases, with a limited inv [...] Read more.
    Rosario Caruso ... Luciana Rigoli
    Published: April 21, 2025 Explor Target Antitumor Ther. 2025;6:1002309
    DOI: https://doi.org/10.37349/etat.2025.1002309
    View:146
    Download:9
    Times Cited: 0
    Open Access
    Review
    Nanoimmunotherapy: the smart trooper for cancer therapy
    Immunotherapy has gathered significant attention and is now a widely used cancer treatment that uses the body’s immune system to fight cancer. Despite initial successes, its broader clinical appli [...] Read more.
    Suphiya Parveen ... Fahima Dilnawaz
    Published: April 10, 2025 Explor Target Antitumor Ther. 2025;6:1002308
    DOI: https://doi.org/10.37349/etat.2025.1002308
    This article belongs to the special issue Comprehensive Immunotherapy of Solid Tumors
    View:376
    Download:13
    Times Cited: 0
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead”  [...] Read more.
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:33055
    Download:3379
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi [...] Read more.
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:21569
    Download:768
    Open Access
    Review
    Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer
    The Fanconi anaemia (FA) pathway is an important mechanism for cellular DNA damage repair, which functions to remove toxic DNA interstrand crosslinks. This is particularly relevant in the context of [...] Read more.
    Sarah J Taylor ... Simon P Langdon
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:26–52
    DOI: https://doi.org/10.37349/etat.2020.00003
    View:8795
    Download:205
    Open Access
    Review
    Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell  [...] Read more.
    Rachael Arthur ... Graham Packham
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:131–152
    DOI: https://doi.org/10.37349/etat.2020.00009
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:8688
    Download:297
    Open Access
    Review
    Novel approaches for the rational design of PROTAC linkers
    Proteolysis targeting chimeras (PROTACs) represent a promising class of hetero-bivalent molecules that facilitate ubiquitination of a target protein by simultaneously binding and bringing together b [...] Read more.
    Almaz Zagidullin ... Emil Bulatov
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381–390
    DOI: https://doi.org/10.37349/etat.2020.00023
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:8480
    Download:500
    Open Access
    Review
    Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response
    Triple negative breast cancer (TNBC) represents an aggressive disease associated with a high risk of recurrence after curative treatment and a poor prognosis in the metastatic setting. Chemotherapy  [...] Read more.
    Pierluigi De Santis ... Palma Fedele
    Published: February 28, 2024 Explor Target Antitumor Ther. 2024;5:232–250
    DOI: https://doi.org/10.37349/etat.2024.00215
    This article belongs to the special issue Innovative Strategies to Target Triple-negative Breast Cancer
    View:8456
    Download:190
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead”  [...] Read more.
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:33055
    Download:3379
    Open Access
    Perspective
    Encouraging probiotics for the prevention and treatment of immune-related adverse events in novel immunotherapies against malignant glioma
    Among the malignant tumors in the central nervous system (CNS), glioma is the most challenging tumor to the public society, which accounts for the majority of intracranial malignant tumors with impa [...] Read more.
    Sayuri Yoshikawa ... Satoru Matsuda
    Published: December 27, 2022 Explor Target Antitumor Ther. 2022;3:817–827
    DOI: https://doi.org/10.37349/etat.2022.00114
    This article belongs to the special issue Theranostic Frontiers in Neuro-Oncology
    View:4866
    Download:1744
    Open Access
    Perspective
    Potential tactics with vitamin D and certain phytochemicals for enhancing the effectiveness of immune-checkpoint blockade therapies
    Immunotherapy strategies targeting immune checkpoint molecules such as programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) are revolutionizing oncology. However,  [...] Read more.
    Ai Tsuji ... Satoru Matsuda
    Published: June 30, 2023 Explor Target Antitumor Ther. 2023;4:460–473
    DOI: https://doi.org/10.37349/etat.2023.00145
    This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment
    View:3711
    Download:1225
    Open Access
    Perspective
    Potential tactics with certain gut microbiota for the treatment of unresectable hepatocellular carcinoma
    Hepatocellular carcinoma (HCC) constitutes an extremely malignant form of primary liver cancer. Intricate connections linking to the immune system might be associated with the pathogenesis of HCC. M [...] Read more.
    Sayuri Yoshikawa ... Satoru Matsuda
    Published: August 24, 2023 Explor Target Antitumor Ther. 2023;4:556–568
    DOI: https://doi.org/10.37349/etat.2023.00152
    This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment
    View:3592
    Download:1121
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi [...] Read more.
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:21569
    Download:768
    Open Access
    Review
    Novel approaches for the rational design of PROTAC linkers
    Proteolysis targeting chimeras (PROTACs) represent a promising class of hetero-bivalent molecules that facilitate ubiquitination of a target protein by simultaneously binding and bringing together b [...] Read more.
    Almaz Zagidullin ... Emil Bulatov
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381–390
    DOI: https://doi.org/10.37349/etat.2020.00023
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:8480
    Download:500
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead”  [...] Read more.
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:33055
    Download:3379
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi [...] Read more.
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:21569
    Download:768
    Open Access
    Review
    Novel approaches for the rational design of PROTAC linkers
    Proteolysis targeting chimeras (PROTACs) represent a promising class of hetero-bivalent molecules that facilitate ubiquitination of a target protein by simultaneously binding and bringing together b [...] Read more.
    Almaz Zagidullin ... Emil Bulatov
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381–390
    DOI: https://doi.org/10.37349/etat.2020.00023
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:8480
    Download:500
    Open Access
    Review
    Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer
    Liquid biopsy is a diagnostic repeatable test, which in last years has emerged as a powerful tool for profiling cancer genomes in real-time with minimal invasiveness and tailoring oncological decisi [...] Read more.
    Vincenza Caputo ... Stefania Napolitano
    Published: February 28, 2023 Explor Target Antitumor Ther 2023;4:102–138
    DOI: https://doi.org/10.37349/etat.2023.00125
    This article belongs to the special issue The Implementation of Liquid Biopsy in Clinical Practice for Different Solid Tumor
    View:5209
    Download:124
    Open Access
    Review
    The clinical advances of proteolysis targeting chimeras in oncology
    Proteolysis targeting chimeras (PROTACs) are a class of small molecules designed to target proteins for degradation. Their novel and unique modes of action provide PROTACs with the potential for the [...] Read more.
    Hao Xie ... Jason B. Fleming
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:511–521
    DOI: https://doi.org/10.37349/etat.2021.00061
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:6098
    Download:234
    Open Access
    Review
    Potential role of resveratrol and its nano-formulation as anti-cancer agent
    The uncontrolled and metastatic nature of cancer makes it worse and more unpredictable. Hence, many therapy and medication are used to control and treat cancer. However, apart from this, many medica [...] Read more.
    Akshay Kumar ... Dilpreet Singh
    Published: October 31, 2022 Explor Target Antitumor Ther. 2022;3:643–658
    DOI: https://doi.org/10.37349/etat.2022.00105
    This article belongs to the special issue Plant Extracts as an Infinite Resource for New Anticancer Agents
    Special Issues